PharmaMar closes the recruitment of the phase III Neptuno study with plitidepsin for the treatment of COVID-19

PharmaMar (MSE: PHM) announced today that it has closed the Phase III Neptuno study with plitidepsin for the treatment of COVID-19 in hospitalized patients.

The company has made this decision due to the lack of patients for study recruitment due to the evolution of the pandemic.

Despite an insufficient sample of patients, a preliminary analysis suggests a positive trend demonstrating the potent activity of the drug.

PharmaMar will continue with the analysis of the study data for its subsequent publication.

Given the evolution of the pandemic and its impact on the number of patients, the company has decided to close the study early.

Preliminary data suggest a positive trend for plitidepsin versus the control arm.

Contact:

Tel: [phone]

Fax: [phone] [e-mail]

(C) 2023 Electronic News Publishing, source ENP Newswire